Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
|
|
Hepion Pharmaceuticals, Inc. (CTRV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 10/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Pre-Funded Warrant",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Sheppard, Mullin, Richter & Hampton LLP Legal Opinion",
"Form of Securities Purchase Agreement",
"Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules EDISON, N.J., September 29, 2023 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis , fibrotic diseases, hepatocellular carcinoma , and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement,..." |
|
| 10/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"CERTIFICATE OF AMENDMENT",
"Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split EDISON, NJ, / May 10, 2023 / Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis , hepatocellular carcinoma , and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023. Hepion common stock will begin trading on a split-adjusted basis when the market opens on May 11, 2023 under the existing trading symbol “HEPA.” As a result of the reverse stock split, the CUSIP number for the Company’ s common stock will now be 42689..." |
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/15/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/21/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/15/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/08/2022 |
8-K
| Quarterly results |
| 10/17/2022 |
8-K
| Investor presentation |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results |
| 07/26/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/20/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/05/2022 |
3
| Reddi Anand (Director) has filed a Form 3 on Hepion Pharmaceuticals, Inc. |
| 06/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/28/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/24/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/14/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/27/2022 |
8-K
| Quarterly results |
|
|
|